▲ +11.53% Upside Potential
This price target is based on 17 analysts offering 12 month price targets for Boston Scientific in the last 3 months. The average price target is $46.53, with a high forecast of $52.00 and a low forecast of $43.00. The average price target represents a 11.53% upside from the last price of $41.72.
The current consensus among 17 contributing investment analysts is to buy stock in Boston Scientific. This Buy consensus rating has held steady for over two years.
Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. It operates through the following segments: Rhythm and Neuro, Cardiovascular and MedSurg. The Rhythm and Neuro segment develops implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. The Cardiovascular segment comprises of technologies or diagnosing and treating coronary artery disease and other cardiovascular disorders including structural heart conditions. The MedSurg segment focuses on Endoscopy, which provides devices to diagnose and treat a broad range of gastrointestinal and pulmonary conditions with innovative and invasive technologies. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.